Drug profile · INN
brinzolamide
AZOPT
brinzolamide (AZOPT) is a carbonic anhydrase ii inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — brinzolamide
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- OPHTHALMIC
- Patents
- 3
- Programs
- 1
- Data quality
- 0.84
Quick answer
brinzolamide (AZOPT) is a carbonic anhydrase ii inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbonic anhydrase II inhibitor
Primary target: Carbonic anhydrase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is brinzolamide?
brinzolamide (AZOPT) is a carbonic anhydrase ii inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for brinzolamide?
AZOPT is a marketed brand name for brinzolamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brinzolamide?
brinzolamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.